Medical comms - Press Releases

Date	Title	Company
09-Dec-2019	Orgenesis launches Point of Care cell and gene therapy centers within HYGEIA Group’s Greek hospital network	HYGEIA Group
09-Dec-2019	Galderma Investigational Therapy Nemolizumab Granted FDA Breakthrough Therapy Designation for the Treatment of Patients Suffering from Prurigo Nodularis	Galderma
09-Dec-2019	Gelesis Secures Over $84 Million in New Capital to Support Commercialization of PLENITY™	Gelesis
09-Dec-2019	Nouscom – First Patient Dosed in a Phase 1 Trial with NOUS-209, an ‘off-the-shelf’ Neoantigen Cancer Vaccine, in MSI-High Solid Tumors	Nouscom
09-Dec-2019	HVIVO (“HVIVO”) to merge with OPEN ORPHAN PLC (“OPEN ORPHAN”)	The Boards of Open Orphan and hVIVO
09-Dec-2019	Moberg Pharma meets primary endpoint for MOB-015 in a Phase 3 study for the treatment of onychomycosis	Moberg Pharma AB
06-Dec-2019	Onyx Health Celebrate ‘Historic Year’ with New Appointments and Double-Digit Growth	Onyx Health
06-Dec-2019	Key Objectives of The Medical Device and In-Vitro Diagnostic Regulations	PharmaLex
06-Dec-2019	Genmab Achieves USD 100 Million Sales Milestone in DARZALEX® (daratumumab) Collaboration with Janssen	Genmab
06-Dec-2019	First Clinical Study Evaluating Combined tDCS And Behaviour Therapy Could Point To A New Treatment For Depression	Flow Neuroscience
05-Dec-2019	Lessons from EU Medical Device Regulation compliance preparations	Kallik
04-Dec-2019	New global survey shows misperceptions about lung cancer among the general public	Lung Ambition Alliance
04-Dec-2019	ASLAN PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF AMERICAN DEPOSITARY SHARES	ASLAN Pharmaceuticals
04-Dec-2019	Micro-Leads Announces $10M in Funding for Precision Neuromodulation Therapy	Albany Med
04-Dec-2019	Volker Koscielny, new Chief Medical Officer and new member of the Management Board at Almirall	Almirall
04-Dec-2019	First UK Clinical Trial Site Open for Recruitment of Diabetic Patients with Chronic Limb-Threatening Ischemia Using Novel Patient-Specific Regenerative Cell Therapy	The University Hospital of Wales
04-Dec-2019	Interview Released Stefan Przyborski, Chairman for SMi’s 3D Cell Culture Conference 2020	SMi Group
04-Dec-2019	Phoenix Solutions AS Strengthens Its Board With the Appointment of Dr. Jean-Michel Cosséry	Phoenix Solutions AS
04-Dec-2019	Chiesi outlines €350 million investment and announces the development of the first carbon minimal pressurised Metered Dose Inhaler (pMDI) for Asthma and COPD	Chiesi Group
04-Dec-2019	Kancera reports in-depth analysis of the Phase Ib program with KAND567, showing the desired effect on the human immune system	Kancera AB